Left to right: Clare Gibbons – Research Manager, Dr. Phillippe Rizek – Neurologist and PI, Rebecca Searles – Research Coordinator
Left to right: Clare Gibbons – Research Manager, Dr. Phillippe Rizek – Neurologist and PI, Rebecca Searles – Research Coordinator
This sites success is down to the dedicated team comprised of study coordinators, principal investigators, clinicians, nurses and lab staff.
This sites success is down to the dedicated team comprised of study coordinators, principal investigators, clinicians, nurses and lab staff.
This simply means that researchers collect samples from the same person more than once over a small period of time. This visit is optional and only offered in the first year of participation. This visit must take place within 1-2 months from the baseline Y0 visit.
This simply means that researchers collect samples from the same person more than once over a small period of time. This visit is optional and only offered in the first year of participation. This visit must take place within 1-2 months from the baseline Y0 visit.
Compared to 2024, where in the first 6 months 123 visits were completed, an additional 84 visits were performed in the first 6 months of 2025. This demonstrates a huge recruitment milestone for our study.
Compared to 2024, where in the first 6 months 123 visits were completed, an additional 84 visits were performed in the first 6 months of 2025. This demonstrates a huge recruitment milestone for our study.
This is a phase-2 clinical trial which is exploring whether lowering levels of the huntingtin protein can slow or stop the progression of HD symptoms.
This is a phase-2 clinical trial which is exploring whether lowering levels of the huntingtin protein can slow or stop the progression of HD symptoms.
AMT-130 is a gene therapy, with the aim of stopping the production of the mutant huntingtin protein (mHTT). A very thin tube, called a micro catheter, is used to deliver micro-RNA to the brain to selectively ‘knockdown’ the huntingtin gene.
AMT-130 is a gene therapy, with the aim of stopping the production of the mutant huntingtin protein (mHTT). A very thin tube, called a micro catheter, is used to deliver micro-RNA to the brain to selectively ‘knockdown’ the huntingtin gene.
Another risk associated with the procedure is lower back pain, but with light activities following the procedure and the type of needle we use, the risk of this event is very low and any discomfort is generally mild.
Another risk associated with the procedure is lower back pain, but with light activities following the procedure and the type of needle we use, the risk of this event is very low and any discomfort is generally mild.
The most common risk associated with the procedure is post LP headaches. These can arise if the procedure causes the pressure inside the head to become too low. Fortunately, this is relatively rare, and when it does happen, it usually resolves without any extra intervention.
The most common risk associated with the procedure is post LP headaches. These can arise if the procedure causes the pressure inside the head to become too low. Fortunately, this is relatively rare, and when it does happen, it usually resolves without any extra intervention.
Then we insert a very fine needle into the lower back to reach the space where the CSF is. A syringe is then used to remove the CSF.
Then we insert a very fine needle into the lower back to reach the space where the CSF is. A syringe is then used to remove the CSF.
Each year, participants undergo “screening” and “sampling” at the study site. Each of these is referred to as a “visit”. They may be separate, or back-to-back on two consecutive days.
There is about a year between annual sampling visits.
Each year, participants undergo “screening” and “sampling” at the study site. Each of these is referred to as a “visit”. They may be separate, or back-to-back on two consecutive days.
There is about a year between annual sampling visits.
We are currently in the process of opening recruitment to the study into other countries, including Melbourne, Australia, and Lisbon, Portugal.
We are currently in the process of opening recruitment to the study into other countries, including Melbourne, Australia, and Lisbon, Portugal.
We collect CSF using a procedure called a lumbar puncture or spinal tap – more about this in detail in future updates.
We collect CSF using a procedure called a lumbar puncture or spinal tap – more about this in detail in future updates.
HDClarity is a longitudinal study, meaning that participants are invited to return for multiple sampling visits, usually about a year apart.
Longitudinal sampling lets us follow how HD changes the brain and body over time.
HDClarity is a longitudinal study, meaning that participants are invited to return for multiple sampling visits, usually about a year apart.
Longitudinal sampling lets us follow how HD changes the brain and body over time.
There are currently 36 sites worldwide that are actively recruiting for the study across Europe, North America, Latin America and Australasia. Our most active sites are currently operating in the United Kingdom and Germany.
There are currently 36 sites worldwide that are actively recruiting for the study across Europe, North America, Latin America and Australasia. Our most active sites are currently operating in the United Kingdom and Germany.
HDClarity is a longitudinal open-ended observational study. The main objective of the study is to collect high-quality cerebrospinal fluid samples for longitudinal evaluation of biomarkers and pathways which will enable the development of novel treatments for #HuntingtonsDisease
HDClarity is a longitudinal open-ended observational study. The main objective of the study is to collect high-quality cerebrospinal fluid samples for longitudinal evaluation of biomarkers and pathways which will enable the development of novel treatments for #HuntingtonsDisease
There are currently 36 sites worldwide that are actively recruiting for the study across Europe, North America, Latin America and Australasia. Our most active sites are currently operating in the United Kingdom and Germany.
There are currently 36 sites worldwide that are actively recruiting for the study across Europe, North America, Latin America and Australasia. Our most active sites are currently operating in the United Kingdom and Germany.
HDClarity is a longitudinal open-ended observational study. The main objective of the study is to collect high-quality cerebrospinal fluid samples for longitudinal evaluation of biomarkers and pathways which will enable the development of novel treatments for #HuntingtonsDisease
HDClarity is a longitudinal open-ended observational study. The main objective of the study is to collect high-quality cerebrospinal fluid samples for longitudinal evaluation of biomarkers and pathways which will enable the development of novel treatments for #HuntingtonsDisease